Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2015

View Archived Issues

Genmab buys anti-DR5 antibodies and IP from iDD Biotech

Selexipag shows efficacy for the treatment of PAH

Stevia and BioViva collaborate on genetic therapies for diabetes and obesity

Vect-Horus discloses neurotensin analogue for therapeutic hypothermia induction

Janssen patents mGluR2 positive allosteric modulators

Bristol-Myers Squibb describes RORgamma modulators

Biogen: new identity for Biogen Idec

Artery Therapeutics presents data on ABCA1 agonist peptide CS-6253

EAU Madrid: Long-term results from the everolimus EXIST-2 trial

High clinical efficacy of ranpirnase demonstrated against HPV infection

Masitinib receives FDA orphan drug designation for amyotrophic lateral sclerosis

Gilead Sciences begins phase I study of GS-5829

Celdara Medical begins phase I trial of chimeric-antigen receptor T cells

Stempeucel receives EMA advanced therapy medicinal product classification

Prozymex patents DPP-I inhibitors

Hayashikane Sangyo develops blood-vessel improving agents

Scancell's SCIB-2 DNA vaccine synergizes with immune checkpoint inhibitors against tumor cells

Orphan Technologies enzyme replacement therapy receives U.S. orphan designation for homocystinuria

University of Copenhagen's placental malaria vaccine ready for phase I studies

World Tuberculosis Day: a reminder about the ongoing epidemic

Medigene initiates first company-sponsored study of DC vaccine for AML

Takeda licenses rights to ImmunoGen's antibody-drug conjugate technology

Cerulean's phase Ib/II trial of CRLX-101 and bevacizumab in RCC meets primary endpoint

Vertex reports on phase II trial of VX-661 and ivacaftor in F508del-homozygous CF

First proof-of-concept for 64Cu-DOTA-AE-105 in bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...